| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | JQ-1 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.4 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.052 | 0.4 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.5 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.04 | 0.5 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |